At a glance
ClinicalIndex Comparison RecordPhase 2Withdrawn· 0 enrolled
Drug / intervention
Fluvoxamine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia (FluCOP Trial)
In Brief
A Phase 2 clinical trial evaluating Fluvoxamine and Placebo for COVID-19 and 2 related conditions. Withdrawn before enrollment, across 1 site.
Signals
Trial was withdrawn before enrollment
Detailed Summary
This study will investigate the efficacy of oral fluvoxamine in olfactory improvement following Covid-19- associated parosmia. This is a randomized, double-blinded, placebo-controlled trial.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19, Olfactory Disorder, Parosmia
CountriesUnited States
Collaborators--
Timeline
Phase 2WithdrawnFinished
20222023202420252026
Enrollment StartDec 2021
First PostedJan 2022
Primary CompletionFeb 2022
TodayJul 2026
First PostedJan 31, 2022
Enrollment StartDec 14, 2021
Primary CompletionFeb 22, 2022
TodayJul 1, 2026
Enrollment to primary: 2 monthsPosted 4.4 years ago
Interventions
Fluvoxaminedrug
Fluvoxamine is an SSRI used for depression and anxiety disorders. This study will investigate the efficacy of fluvoxamine for improvement of olfactory dysfunction in subjects with post-Covid-19 parosmia.
Placebodrug
lactose placebo capsules identical to fluvoxamine capsules in order to preserve blind